---
annotations:
- type: Pathway Ontology
  value: epidermal growth factor/neuregulin signaling pathway
authors:
- MaintBot
- Khanspers
- ReactomeTeam
- Anwesha
description: The epidermal growth factor receptor (EGFR) is one member of the ERBB
  family of transmembrane glycoprotein tyrosine receptor kinases (RTK). Binding of
  EGFR to its ligands induces conformational change that unmasks the dimerization
  interface in the extracellular domain of EGFR, leading to receptor homo- or heterodimerization
  at the cell surface. Dimerization of the extracellular regions of EGFR triggers
  additional conformational change of the cytoplasmic EGFR regions, enabling the kinase
  domains of two EGFR molecules to achieve the catalytically active conformation.
  Ligand activated EGFR dimers trans-autophosphorylate on tyrosine residues in the
  cytoplasmic tail of the receptor. Phosphorylated tyrosines serve as binding sites
  for the recruitment of signal transducers and activators of intracellular substrates,
  which then stimulate intracellular signal transduction cascades that are involved
  in regulating cellular proliferation, differentiation, and survival. Recruitment
  of complexes containing GRB2 and SOS1 to phosphorylated EGFR dimers either directly,
  through phosphotyrosine residues that serve as GRB2 docking sites, or indirectly,
  through SHC1 recruitment, promotes GDP to GTP exchange on RAS, resulting in the
  activation of RAF/MAP kinase cascade. Binding of complexes of GRB2 and GAB1 to phosphorylated
  EGFR dimers leads to formation of the active PI3K complex, conversion of PIP2 into
  PIP3, and activation of AKT signaling. Phospholipase C-gamma1 (PLCG1) can also be
  recruited directly, through EGFR phosphotyrosine residues that serve as PLCG1 docking
  sites, which leads to PLCG1 phosphorylation by EGFR and activation of DAG and IP3
  signaling. EGFR signaling is downregulated by the action of ubiquitin ligase CBL.
  CBL binds directly to the phosphorylated EGFR dimer through the phosphotyrosine
  Y1045 in the C-tail of EGFR, and after CBL is phosphorylated by EGFR, it becomes
  active and ubiquitinates phosphorylated EGFR dimers, targeting them for degradation.
  For a recent review of EGFR signaling, please refer to Avraham and Yarden, 2011.   View
  original pathway at:[http://www.reactome.org/PathwayBrowser/#DIAGRAM=177929 Reactome].
last-edited: 2018-11-01
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP1910
- /instance/WP1910
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP1910.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: The epidermal growth factor receptor (EGFR) is one member of the ERBB
    family of transmembrane glycoprotein tyrosine receptor kinases (RTK). Binding
    of EGFR to its ligands induces conformational change that unmasks the dimerization
    interface in the extracellular domain of EGFR, leading to receptor homo- or heterodimerization
    at the cell surface. Dimerization of the extracellular regions of EGFR triggers
    additional conformational change of the cytoplasmic EGFR regions, enabling the
    kinase domains of two EGFR molecules to achieve the catalytically active conformation.
    Ligand activated EGFR dimers trans-autophosphorylate on tyrosine residues in the
    cytoplasmic tail of the receptor. Phosphorylated tyrosines serve as binding sites
    for the recruitment of signal transducers and activators of intracellular substrates,
    which then stimulate intracellular signal transduction cascades that are involved
    in regulating cellular proliferation, differentiation, and survival. Recruitment
    of complexes containing GRB2 and SOS1 to phosphorylated EGFR dimers either directly,
    through phosphotyrosine residues that serve as GRB2 docking sites, or indirectly,
    through SHC1 recruitment, promotes GDP to GTP exchange on RAS, resulting in the
    activation of RAF/MAP kinase cascade. Binding of complexes of GRB2 and GAB1 to
    phosphorylated EGFR dimers leads to formation of the active PI3K complex, conversion
    of PIP2 into PIP3, and activation of AKT signaling. Phospholipase C-gamma1 (PLCG1)
    can also be recruited directly, through EGFR phosphotyrosine residues that serve
    as PLCG1 docking sites, which leads to PLCG1 phosphorylation by EGFR and activation
    of DAG and IP3 signaling. EGFR signaling is downregulated by the action of ubiquitin
    ligase CBL. CBL binds directly to the phosphorylated EGFR dimer through the phosphotyrosine
    Y1045 in the C-tail of EGFR, and after CBL is phosphorylated by EGFR, it becomes
    active and ubiquitinates phosphorylated EGFR dimers, targeting them for degradation.
    For a recent review of EGFR signaling, please refer to Avraham and Yarden, 2011.   View
    original pathway at:[http://www.reactome.org/PathwayBrowser/#DIAGRAM=177929 Reactome].
  keywords:
  - EGF:p-6Y-EGFR:CBL:Beta-Pix:CDC42:GTP:CIN85
  - 'UBB(1-76) '
  - EGFRvIII
  - 'EPS15L1 '
  - mutant:HSP90:CDC37
  - PIP3 activates AKT
  - EGF:p-6Y-EGFR:CBL:Ub-p-Y53/55-SPRY1/2
  - 'EGFR L858R '
  - EGF:p-6Y-EGFR:CBL:p-Y53/55-SPRY1/2
  - SRC-1
  - EGF:p-6Y-EGFR:p-Y349,350-SHC1:GRB2:SOS1
  - 'HGS '
  - 'PTPN11 '
  - 'SH3GL2 '
  - GRB2-1
  - EGFR
  - 'EGFR M766_A767insASV '
  - CSK
  - 'UBC(609-684) '
  - 'IPI-504 '
  - 'PXN '
  - GDP
  - EGF:p-6Y-EGFR:GRB2:p-5Y-GAB1
  - EGF:p-6Y-EGFR:CBL
  - EGFR:Cetuximab
  - 'p-Y53-SPRY1 '
  - EGF:Ub-p-6Y-EGFR:p-Y371-CBL
  - 'PLCG1 '
  - 'PI(4,5)P2 '
  - mutants:Covalent
  - 'SH3KBP1 '
  - 'EGFR D770_N771insNPG '
  - EGF:EGFR
  - Covalent EGFR
  - '17-DMAG '
  - EGF:p-6Y-EGFR:p-Y371-CBL:Ub-CIN85:Endophilin:Epsin:Eps15L1:Eps15
  - 'UBB(153-228) '
  - EGF:p-6Y-EGFR:CBL:Beta-Pix:CDC42:GTP
  - CBL:SPRY1/2
  - 'EGFR E746_A750del;T790M '
  - mutants:Non-covalent EGFR TKIs
  - 'SPRY2 '
  - 'STAM2 '
  - 'p-6Y-EGFR '
  - 'GAB1 '
  - 'UBC(1-76) '
  - 'SOS1 '
  - 'EGFR T263P '
  - EGF:p-6Y-EGFR:GRB2:p-Y627,659-GAB1:SHP2
  - 'EGFR '
  - EGF:p-6Y-EGFR:PLCG1
  - 'p-Y-PXN '
  - EGF:Ligand-responsive EGFR mutants:HSP90:CDC37
  - EGFR mutants
  - PTPN12
  - CDC37
  - 'UBC(77-152) '
  - p-Y317-PAG1
  - mutants:HSP90:CDC37
  - 'PIK3CA '
  - EGF:p-6Y-EGFR:p-Y371-CBL:CIN85:SPRY1/2:Endophilin:Epsin:Eps15L1:EPS15
  - 'ARHGEF7 '
  - 'SH3GL3 '
  - inhibitors
  - 'EGF '
  - Beta-Pix:CDC42:GTP
  - 'STAM '
  - GAB1
  - GRB2:GAB1:PIP3
  - Ub-Beta-Pix:CDC42:GTP
  - signaling
  - PTPN3
  - 'CBL '
  - EGF:p-6Y-EGFR:p-Y371-CBL:GRB2:CIN85:Endophilin:EPN1:EPS15L1:p-EPS15:HGS:STAM
  - EGFR TKIs
  - 'EGFR L858R;T790M '
  - EGF:p-6Y-EGFR:p-Y472,771,783,1254-PLCG1
  - EGF:p-6Y-EGFR:p-Y349,350-SHC1
  - 'GRB2-1 '
  - 'ADAM17 '
  - Pi
  - 'p-4Y-EGFR '
  - 'KRAS '
  - Ub
  - 'MyrG-SRC '
  - PAG1
  - 'EGFRvIII '
  - EGF:Ligand-responsive EGFR mutants dimer
  - 'p-5Y-GAB1 '
  - 'Ligand-responsive EGFR mutants sensitive to non-covalent TKIs '
  - ATP
  - 'UBA52(1-76) '
  - 'p-4Y-PLCG1 '
  - 'p-Y627,Y659-GAB1 '
  - 'Cetuximab '
  - 'UBC(457-532) '
  - Cetuximab
  - PI(4,5)P2
  - H2O
  - 'p-Y992,Y1045,Y1068,Y1086,Y1173-EGFR '
  - EPN1
  - 'CSK '
  - 'ADAM10(215-824) '
  - 'UBC(153-228) '
  - EGF:p-6Y-EGFR:GRB2:GAB1
  - Dimer:Covalent EGFR
  - 'EGFR G719S '
  - 'EGFR E746_T751delinsA '
  - EGF
  - Benzoquinoid
  - dephosphorylated at
  - HSP90
  - CBL
  - EGF:p-6Y-EGFR:p-Y371-CBL:CIN85:Endophilin:Epsin:Eps15L1:Eps15
  - EGF:p-EGFR dimer
  - 'EGFR L747_A750delinsP '
  - 'HSP90AA1 '
  - EGFRvIII mutant
  - 'Geldanamycin '
  - EGF:p-6Y-EGFR:p-Y371-CBL:GRB2
  - 'p-Y55-SPRY2 '
  - PXN:MyrG-SRC
  - PIK3CA:PIK3R1
  - 'Ligand-responsive EGFR mutants resistant to non-covalent TKIs '
  - Active dimers of
  - CIN85:endophilin
  - 'UBC(381-456) '
  - 'Irreversible EGFR-specific TKIs '
  - 'EGFR E746_A750del '
  - SHC1
  - '17-AAG '
  - TKIs
  - EGF:p-6Y-EGFR:p-Y371-CBL:GRB2:CIN85:Endophilin
  - 'p-Y850 EPS15 '
  - EPS15:HGS:STAM
  - PTPN11
  - 'UBC(229-304) '
  - EGF:Ub-p-6Y-EGFR:p-Y371-CBL:GRB2
  - 'EGFR G719A '
  - EGF:p-6Y-EGFR:GRB2:p-5Y-GAB1:PI3K
  - Y1148 (Y1172)
  - 'ADAM12 '
  - 'PIK3R1 '
  - p21 RAS:GTP
  - 'EGFR G719C '
  - 'Herbimycin A '
  - EGF:p-6Y-EGFR:p-Y371-CBL
  - 'EGFR L747_S752del '
  - 'SH3GL1 '
  - ADAM:Zn2+
  - 'p-Y371-CBL '
  - CBL:Beta-Pix:CDC42:GTP
  - Pro-EGF
  - 'PI(3,4,5)P3 '
  - 'EGFR A289T '
  - 'Irreversible anti-EGFRplus TKIs '
  - GRB2-1:SOS1
  - EGF:EGFR dimer
  - EGF:p-6Y-EGFR:GRB2:p-5Y-GAB1:SHP2
  - CBL:GRB2
  - 'EGFR G598V '
  - EGF:p-5Y-EGFR:GRB2:p-5Y-GAB1:SHP2
  - 'EGFR L747_T751del '
  - EGF:p-6Y-EGFR dimer
  - 'EGFR L747_T751delinsP '
  - tyrosine kinase
  - EGF:p-6Y-EGFR:GRB2:SOS1
  - ansamycins
  - EGF:p-6Y-EGFR:SHC1
  - PLCG1
  - 'EGFR L747_P753delinsS '
  - cascade
  - 'EGFR R108K '
  - 'EGFR V738_K739insKIPVAI '
  - Resistant
  - EGF:p-6Y-EGFR:p-Y371-CBL:GRB2:CIN85:Endophilin:EPN1:EPS15L1:EPS15:HGS:STAM
  - PI(3,4,5)P3
  - 'GDP '
  - GRB2:GAB1,GRB2:GAB1:PIP3
  - 'RPS27A(1-76) '
  - p-4Y-PLCG1
  - p-Y-PXN:CSK:MyrG,p-Y530-SRC
  - 'EPS15 '
  - 'UBB(77-152) '
  - 'EGFR A289D '
  - RAF/MAP kinase
  - 'UBC(533-608) '
  - 'NRAS '
  - 'Ub-SH3KBP1 '
  - 'Reversible anti-EGFRplus TKIs '
  - GTP
  - Ligand-responsive
  - p-Y55-SPRY2
  - Sensitive
  - 'p-Y349,Y350-SHC1 '
  - 'MyrG,p-Y530-SRC '
  - EGF:p-6Y-EGFR:CBL:GRB2
  - LRIG1
  - HSP90:Benzoquinoid
  - 'EGFR A289V '
  - 'Reversible EGFR-specific TKIs '
  - p21 RAS:GDP
  - EGFR mutants dimer
  - PTPRK
  - EPS15L1
  - DAG and IP3
  - ligand-responsive
  - dimer
  - 'UBC(305-380) '
  - SPRY1/2
  - 'HRAS '
  - ADP
  - 'SPRY1 '
  - GRB2:GAB1
  - 'CDC42 '
  - 'Zn2+ '
  - 'GTP '
  - 'SHC1 '
  - Non-covalent EGFR
  - 'EGFR D770_N771insNPH '
  - 'EPN1 '
  - 'CDC37 '
  - 'EGFR E746_S752delinsV '
  - SOS1
  - 'EGFR L861Q '
  license: CC0
  name: Signaling by EGFR
seo: CreativeWork
title: Signaling by EGFR
wpid: WP1910
---